Health
Emyria to seek approval for trial evaluating MDMA to treat PTSD – Stockhead
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder…
Link copied toclipboard
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder was rejected on ethics grounds, an ASX-listed drug development company is taking another crack at it.
Emyria (ASX:EMD) announced this morning that in partnership with Mind Medicine Australia it would seek approval for a major clinical trial testing the use of MDMA to alleviate treatment-resistant PTSD.
Emyria managing…
-
Noosa News18 hours agoYoung voices shape Sunshine Coast’s future
-
Business18 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News16 hours agoAnother All-Star Cast, Another Tale of Family Chaos: The Trailer for Wes Anderson’s ‘The Phoenician Scheme’ Is Here
-
Business15 hours agoshould I buy hedged or unhedged ASX US-focused ETFs?